

115TH CONGRESS  
2D SESSION

**S.** \_\_\_\_\_

To authorize the Secretary of Health and Human Services to conduct programs to address the usage of illicit drugs, particularly fentanyl, and for other purposes.

---

IN THE SENATE OF THE UNITED STATES

Ms. WARREN introduced the following bill; which was read twice and referred to the Committee on \_\_\_\_\_

---

**A BILL**

To authorize the Secretary of Health and Human Services to conduct programs to address the usage of illicit drugs, particularly fentanyl, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Surveillance and Test-  
5 ing of Opioids to Prevent Fentanyl Deaths Act of 2018”  
6 or the “STOP Fentanyl Deaths Act of 2018”.

1 **SEC. 2. PUBLIC HEALTH LABORATORIES TO DETECT**  
2 **FENTANYL.**

3 (a) IN GENERAL.—The Secretary of Health and  
4 Human Services (in this section referred to as the “Sec-  
5 retary”) shall establish a program to award grants to Fed-  
6 eral, State, and local agencies to support the establish-  
7 ment or operation of public health laboratories to detect  
8 fentanyl, its analogues, and other synthetic opioids, as de-  
9 scribed in subsection (b).

10 (b) STANDARDS.—The Secretary, in consultation  
11 with the Director of the National Institute of Standards  
12 and Technology, shall—

13 (1) develop standards for effectively handling  
14 and testing fentanyl, its analogues, and other syn-  
15 thetic opioids;

16 (2) develop—

17 (A) fentanyl and fentanyl analogue ref-  
18 erence materials, quality control standards, and  
19 protocols to calibrate instrumentation for clin-  
20 ical diagnostics and post-mortem surveillance;  
21 and

22 (B) portable testing devices utilized by law  
23 enforcement and public health officials; and

24 (3) include in the standards developed pursuant  
25 to paragraph (1) procedures for encountering new  
26 and emerging synthetic opioid formulations and re-

1 port those findings to Federal, State, and local pub-  
2 lic health laboratories.

3 (c) LABORATORIES.—The Secretary shall require  
4 grantees under subsection (a) to—

5 (1) follow the standards established under sub-  
6 section (b) and be capable of providing systematic  
7 and routine laboratory testing of drugs for the pur-  
8 poses of obtaining and disseminating public health  
9 information to Federal, State, and local public  
10 health officials, laboratories, and other entities as  
11 the Secretary determines appropriate;

12 (2) work with law enforcement agencies and  
13 public health authorities, as practicable, to develop  
14 real-time information on the purity and movement of  
15 fentanyl, its analogues, and other synthetic opioids;

16 (3) assist State and local law enforcement agen-  
17 cies in testing seized drugs when State and local fo-  
18 rensic laboratories request additional assistance;

19 (4) provide early warning information and ad-  
20 vice to Federal, State, and local law enforcement  
21 agencies and public health authorities of potential  
22 significant changes in the supply of fentanyl, its  
23 analogues, and other synthetic opioids;

1           (5) provide biosurveillance for non-fatal expo-  
2           sures to fentanyl, fentanyl analogues, and other syn-  
3           thetic opioids; and

4           (6) provide diagnostic testing for such non-fatal  
5           exposures to emergency personnel.

6           (d) AUTHORIZATION OF APPROPRIATIONS.—To carry  
7           out this section, there is authorized to be appropriated  
8           \$15,000,000 for each of fiscal years 2019 through 2023.

9           **SEC. 3. ENHANCED FENTANYL SURVEILLANCE.**

10          (a) IN GENERAL.—The Director of the Centers for  
11          Disease Control and Prevention shall enhance its drug  
12          surveillance program by—

13               (1) expanding its surveillance program to in-  
14               clude all 50 States and the territories of the United  
15               States;

16               (2) increasing and accelerating the collection of  
17               data on fentanyl, its analogues, other synthetic  
18               opioids, and new emerging drugs of abuse, including  
19               related overdose data from medical examiners and  
20               drug treatment admissions; and

21               (3) utilizing available and emerging information  
22               on fentanyl, its analogues, other synthetic opioids,  
23               and new emerging drugs of abuse, including infor-  
24               mation from—

1 (A) the National Drug Early Warning Sys-  
2 tem;

3 (B) State and local public health authori-  
4 ties; and

5 (C) Federal, State, and local public health  
6 laboratories.

7 (b) AUTHORIZATION OF APPROPRIATIONS.—To carry  
8 out this section, there is authorized to be appropriated  
9 \$10,000,000 for each of fiscal years 2019 through 2023.